Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment

Claudia Maria Hattinger, Maria Pia Patrizio, Silvia Luppi, Federica Magagnoli, Piero Picci, Massimo Serra

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: DNA damaging drugs are widely used for the chemotherapeutic treatment of high-grade osteosarcoma (HGOS). In HGOS patients, several germline polymorphisms have been reported to impact on the development of adverse toxic events related to DNA damaging drugs treatment. Some of these polymorphisms, when present in tumor cells, may also influence treatment response and prognosis of HGOS patients. Area covered. In this review, the authors have focused on pharmacogenetic markers (mainly germline polymorphisms) described in patients with HGOS, which have proved or indicated to be related to the susceptibility to adverse toxic reactions and/or to influence response to DNA damaging drugs. The concordant and discordant results reported in different studies have also been discussed. Expert Opinion. Response and toxicity predisposition to DNA damaging drugs are influenced by genes encoding proteins involved in their uptake, efflux, activation, inactivation, and in DNA repair, activity of which may vary according to specific gene variations. In HGOS, there is a substantial medical need for biomarkers predictive for individual response and toxicity predisposition to DNA-targeting drugs, which may be used to tailor therapy in order to decrease the occurrence of adverse side effects and increase treatment efficacy and safety.

Original languageEnglish
Pages (from-to)299-311
Number of pages13
JournalExpert opinion on drug metabolism & toxicology
Volume15
Issue number4
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Pharmacogenetics
Osteosarcoma
DNA
Polymorphism
Pharmaceutical Preparations
Poisons
Toxicity
Therapeutics
Drug therapy
Expert Testimony
Drug Delivery Systems
Gene encoding
DNA Repair
Biomarkers
Tumors
Repair
Safety
Genes
Chemical activation
Cells

Keywords

  • ABC transporters
  • DNA damage
  • DNA repair
  • ERCC1
  • GST
  • detoxification
  • germline polymorphisms
  • osteosarcoma
  • pharmacogenetics
  • toxicity

Cite this

Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment. / Hattinger, Claudia Maria; Patrizio, Maria Pia; Luppi, Silvia; Magagnoli, Federica; Picci, Piero; Serra, Massimo.

In: Expert opinion on drug metabolism & toxicology, Vol. 15, No. 4, 01.04.2019, p. 299-311.

Research output: Contribution to journalArticle

@article{db030491dcb846c2a6c5f7fe2386d27a,
title = "Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment",
abstract = "INTRODUCTION: DNA damaging drugs are widely used for the chemotherapeutic treatment of high-grade osteosarcoma (HGOS). In HGOS patients, several germline polymorphisms have been reported to impact on the development of adverse toxic events related to DNA damaging drugs treatment. Some of these polymorphisms, when present in tumor cells, may also influence treatment response and prognosis of HGOS patients. Area covered. In this review, the authors have focused on pharmacogenetic markers (mainly germline polymorphisms) described in patients with HGOS, which have proved or indicated to be related to the susceptibility to adverse toxic reactions and/or to influence response to DNA damaging drugs. The concordant and discordant results reported in different studies have also been discussed. Expert Opinion. Response and toxicity predisposition to DNA damaging drugs are influenced by genes encoding proteins involved in their uptake, efflux, activation, inactivation, and in DNA repair, activity of which may vary according to specific gene variations. In HGOS, there is a substantial medical need for biomarkers predictive for individual response and toxicity predisposition to DNA-targeting drugs, which may be used to tailor therapy in order to decrease the occurrence of adverse side effects and increase treatment efficacy and safety.",
keywords = "ABC transporters, DNA damage, DNA repair, ERCC1, GST, detoxification, germline polymorphisms, osteosarcoma, pharmacogenetics, toxicity",
author = "Hattinger, {Claudia Maria} and Patrizio, {Maria Pia} and Silvia Luppi and Federica Magagnoli and Piero Picci and Massimo Serra",
year = "2019",
month = "4",
day = "1",
doi = "10.1080/17425255.2019.1588885",
language = "English",
volume = "15",
pages = "299--311",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment

AU - Hattinger, Claudia Maria

AU - Patrizio, Maria Pia

AU - Luppi, Silvia

AU - Magagnoli, Federica

AU - Picci, Piero

AU - Serra, Massimo

PY - 2019/4/1

Y1 - 2019/4/1

N2 - INTRODUCTION: DNA damaging drugs are widely used for the chemotherapeutic treatment of high-grade osteosarcoma (HGOS). In HGOS patients, several germline polymorphisms have been reported to impact on the development of adverse toxic events related to DNA damaging drugs treatment. Some of these polymorphisms, when present in tumor cells, may also influence treatment response and prognosis of HGOS patients. Area covered. In this review, the authors have focused on pharmacogenetic markers (mainly germline polymorphisms) described in patients with HGOS, which have proved or indicated to be related to the susceptibility to adverse toxic reactions and/or to influence response to DNA damaging drugs. The concordant and discordant results reported in different studies have also been discussed. Expert Opinion. Response and toxicity predisposition to DNA damaging drugs are influenced by genes encoding proteins involved in their uptake, efflux, activation, inactivation, and in DNA repair, activity of which may vary according to specific gene variations. In HGOS, there is a substantial medical need for biomarkers predictive for individual response and toxicity predisposition to DNA-targeting drugs, which may be used to tailor therapy in order to decrease the occurrence of adverse side effects and increase treatment efficacy and safety.

AB - INTRODUCTION: DNA damaging drugs are widely used for the chemotherapeutic treatment of high-grade osteosarcoma (HGOS). In HGOS patients, several germline polymorphisms have been reported to impact on the development of adverse toxic events related to DNA damaging drugs treatment. Some of these polymorphisms, when present in tumor cells, may also influence treatment response and prognosis of HGOS patients. Area covered. In this review, the authors have focused on pharmacogenetic markers (mainly germline polymorphisms) described in patients with HGOS, which have proved or indicated to be related to the susceptibility to adverse toxic reactions and/or to influence response to DNA damaging drugs. The concordant and discordant results reported in different studies have also been discussed. Expert Opinion. Response and toxicity predisposition to DNA damaging drugs are influenced by genes encoding proteins involved in their uptake, efflux, activation, inactivation, and in DNA repair, activity of which may vary according to specific gene variations. In HGOS, there is a substantial medical need for biomarkers predictive for individual response and toxicity predisposition to DNA-targeting drugs, which may be used to tailor therapy in order to decrease the occurrence of adverse side effects and increase treatment efficacy and safety.

KW - ABC transporters

KW - DNA damage

KW - DNA repair

KW - ERCC1

KW - GST

KW - detoxification

KW - germline polymorphisms

KW - osteosarcoma

KW - pharmacogenetics

KW - toxicity

U2 - 10.1080/17425255.2019.1588885

DO - 10.1080/17425255.2019.1588885

M3 - Article

C2 - 30822170

VL - 15

SP - 299

EP - 311

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 4

ER -